empagliflozin/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Decreases cardiovascular mortality
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×1“Empagliflozin reduced all-cause mortality (OR: 0.47, 95% CI: 0.29-0.78, p = 0.004) and cardiovascular death (OR: 0.56, 95% CI: 0.38-0.82, p = 0.003) compared to placebo.”
Quoted verbatim from Efficacy and safety of empagliflozin in acute heart failure: a systematic review and meta-analysis.. - Study
- meta-analysis
- Population
- Adults with acute heart failure; pooled randomised placebo-controlled trials
Effect 0.56 odds ratio, 95% CI 0.38 to 0.82
Efficacy and safety of empagliflozin in acute heart failure: a systematic review and meta-analysis.2025PMID:40324865Permalink
Keep reading
- Everything the graph holds on empagliflozin
- Every compound studied against Cardiovascular mortality
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M45EE0N6X2JKAM6GS8BZXM5Y